Department of Microbiology and Molecular Genetics, Michigan State University, East Lansing, MI 48824, USA.
Viruses. 2024 Feb 16;16(2):302. doi: 10.3390/v16020302.
There is great enthusiasm toward the development of novel immunotherapies for the treatment of cancer, and given their roles in immune system regulation, chemokines stand out as promising candidates for use in new cancer therapies. Many previous studies have shown how chemokine signaling pathways could be targeted to halt cancer progression. We and others have revealed that the chemokine CXCL14 promotes antitumor immune responses, suggesting that CXCL14 may be effective for cancer immunotherapy. However, it is still unknown what mechanism governs CXCL14-mediated antitumor activity, how to deliver CXCL14, what dose to apply, and what combinations with existing therapy may boost antitumor immune responses in cancer patients. Here, we provide updates on the role of CXCL14 in cancer progression and discuss the potential development and application of CXCL14 as an immunotherapeutic agent.
人们对开发新型免疫疗法治疗癌症的热情高涨,趋化因子在免疫系统调节中发挥着重要作用,因此它们成为癌症新疗法中极具应用前景的候选药物。许多先前的研究表明,趋化因子信号通路可以作为阻止癌症进展的靶点。我们和其他人的研究揭示了趋化因子 CXCL14 可促进抗肿瘤免疫反应,提示 CXCL14 可能对癌症免疫治疗有效。但是,目前尚不清楚何种机制控制 CXCL14 介导的抗肿瘤活性,如何递送 CXCL14,应用何种剂量,以及与现有治疗方法的何种组合可增强癌症患者的抗肿瘤免疫反应。本文就 CXCL14 在癌症进展中的作用提供最新研究进展,并讨论 CXCL14 作为免疫治疗药物的潜在开发和应用。